352 related articles for article (PubMed ID: 30875928)
1. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le T; Gerber DE
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875928
[TBL] [Abstract][Full Text] [Related]
2. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
6. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
Mountzios G
Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
Doval DC; Desai CJ; Sahoo TP
Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
[TBL] [Abstract][Full Text] [Related]
8. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
Tatineni V; O'Shea PJ; Ozair A; Khosla AA; Saxena S; Rauf Y; Jia X; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190312
[No Abstract] [Full Text] [Related]
9. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
Saad N; Poudel A; Basnet A; Gajra A
Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
[TBL] [Abstract][Full Text] [Related]
10. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation
Sullivan I; Planchard D
Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.
Masuzawa K; Yasuda H; Hamamoto J; Nukaga S; Hirano T; Kawada I; Naoki K; Soejima K; Betsuyaku T
Oncotarget; 2017 Dec; 8(62):105479-105491. PubMed ID: 29285266
[TBL] [Abstract][Full Text] [Related]
13. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced
Zhang D; Liu X; Shen F; Zhao D; Shi Y; Zhang H; Liu J; Gao X; Chen M; Zhao J; Zhong W; Gao J; He M; Liu Y; Yang X; Qin J; Tang Y; Mu X; Gu Y; Zhang S; Chen X; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; Li Q; Li Y; Chen J; Gao F; Jin B; Rossi A; Adachi H; Guerrera F; Husain H; Xu Y; Wang M
Transl Lung Cancer Res; 2023 Nov; 12(11):2229-2244. PubMed ID: 38090527
[TBL] [Abstract][Full Text] [Related]
15. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study.
Tsukita Y; Inoue A
Jpn J Clin Oncol; 2022 Apr; ():. PubMed ID: 35446957
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib.
Malapelle U; Ricciuti B; Baglivo S; Pepe F; Pisapia P; Anastasi P; Tazza M; Sidoni A; Liberati AM; Bellezza G; Chiari R; Metro G
Recent Results Cancer Res; 2018; 211():257-276. PubMed ID: 30069773
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use.
Scott LJ
Drugs Ther Perspect; 2018; 34(8):351-357. PubMed ID: 30631243
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib - effective treatment of NSCLC with activating
Skrzypski M; Szymanowska-Narloch A; Dziadziuszko R
Contemp Oncol (Pozn); 2017; 21(3):254-258. PubMed ID: 29180936
[TBL] [Abstract][Full Text] [Related]
20. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
